Key Points
- Director David Epstein bought 10,000 AgomAb shares at an average price of $8.88, investing $88,800 and increasing his holdings by 66.67% to 25,000 shares.
- AgomAb shares opened at $9.26, up 1.6%, but remained below their 50-day and 200-day moving averages of $11.60 and $11.77, respectively. The company reported a quarterly loss of $0.46 per share, with analysts expecting a full-year loss of $1.83 per share.
- Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating from eight Buy and one Hold recommendation and an average price target of $37.50; however, Wall Street Zen downgraded the stock to Sell.
AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein purchased 10,000 shares of the stock in a transaction dated Wednesday, October 21st. The shares were purchased at an average price of $8.88 per share, with a total value of $88,800.00. Following the completion of the transaction, the director owned 25,000 shares of the company's stock, valued at approximately $222,000. This trade represents a 66.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
AgomAb Therapeutics Stock Up 1.6%
Shares of NASDAQ AGMB opened at $9.26 on Friday. AgomAb Therapeutics NV has a twelve month low of $7.92 and a twelve month high of $17.82. The stock has a fifty day simple moving average of $11.60 and a 200-day simple moving average of $11.77.
AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, analysts anticipate that AgomAb Therapeutics NV will post -1.83 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on AGMB. HC Wainwright reaffirmed a "buy" rating on shares of AgomAb Therapeutics in a research report on Wednesday. Wall Street Zen cut shares of AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 27th. Johnson Rice reissued a "buy" rating on shares of AgomAb Therapeutics in a research note on Wednesday. Piper Sandler assumed coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an "overweight" rating for the company. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.50.
Get Our Latest Report on AgomAb Therapeutics
AgomAb Therapeutics Company Profile
(
Get Free Report)
Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company's research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.
Agomab's lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn's disease, a condition in which scar tissue can narrow the intestine and contribute to complications.
The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
